[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Sanitaria Locale CN2 Alba-Bra\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100624889","breast-density-impact-on-mammographic-screening-for-breast-cancer-diagnosis-100624889",false,"NCT07415499","Breast Density Impact on Mammographic Screening for Breast Cancer Diagnosis","Retrospective Study on Patients Undergoing Mammographic Screening to Evaluate the Impact of Breast Density on Breast Cancer Diagnosis","SINATRA","Inclusion Criteria:\n\n* Women aged 45 to 75 years who participated in the \"Prevenzione Serena\" mammography screening program and underwent screening mammography at ASL CN2 between September 25, 2023, and May 3, 2024.\n* Signed informed consent or equivalent substitute declaration, when applicable.\n\nExclusion Criteria:\n\n* Women with a history of mastectomy.\n* Women with breast implants.\n* Women with cardiac implantable devices, such as pacemakers or loop recorders.\n* Cases in which the Insight BD software cannot be applied due to compression thickness below 15 mm.","FEMALE","45 Years","75 Years",{"count":21,"type":22},3300,"ESTIMATED","OBSERVATIONAL","This retrospective, observational study aims to evaluate how breast density affects the accuracy and outcomes of mammographic screening for breast cancer within the regional screening program \"Prevenzione Serena\".\n\nBreast density is an important factor because dense breast tissue can make it more difficult to detect breast cancer on a mammogram. Dense tissue and tumors both appear white on a mammogram, which may hide abnormalities and lead to missed cancers or false-positive results.\n\nWomen aged 45 to 75 years who underwent routine mammographic screening at ASL CN2 between September 2023 and May 2024 will be included. Breast density will be classified using the BI-RADS system (categories A-D), and the study will assess whether women with dense breasts (categories C and D) experience higher rates of recalls for second-level examinations such as ultrasound, MRI, etc).\n\nThe study also includes an internal validation of Insight BD, an automated breast-density measurement software used at ASL CN2. The software will be evaluated using a mammography phantom (to verify technical accuracy) and by comparing its BI-RADS density classifications with readings from two radiologists (one expert and one less experienced). This will help determine whether the software can support radiologists, especially in evaluating dense breast tissue.\n\nAdditional factors such as menopausal status, family history of breast cancer, and hormone therapy will also be examined to understand how they relate to breast density and screening outcomes. The study aims to quantify the frequency of false-positive recalls-cases in which additional tests are recommended but cancer is not found-because these events can increase patient anxiety and healthcare workload.\n\nUltimately, this research seeks to provide evidence that may inform future screening guidelines and support more personalized approaches, particularly for women with dense breasts.",[26,27],"Breast Cancer Screening","Breast Cancer Screening and Diagnosis",[29,30,31,32,33,34],"Breast cancer","Breast cancer screening","BRADS","Mammography","Dense breast","Breast imaging","RECRUITING","2026-02-16",{"date":38,"type":39},"2026-02-17","ACTUAL",{"date":41,"type":39},"2026-01-12",{"date":43,"type":22},"2026-09",{"name":45,"class":46},"Azienda Sanitaria Locale CN2 Alba-Bra","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100617371","incidence-of-dysgeusia-in-breast-cancer-patients-undergoing-chemotherapy-100617371","NCT07317752","Incidence of Dysgeusia in Breast Cancer Patients Undergoing Chemotherapy","Incidenza Della Disgeusia Nei Pazienti Affetti da Carcinoma Mammario in Trattamento Chemioterapico: Uno Studio Pilota Prospettico","GustiAmo","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of non-metastatic breast cancer\n* Indication for neoadjuvant or adjuvant chemotherapy as part of standard clinical practice\n* Chemotherapy-naïve patients (no chemotherapy received in the previous 12 months)\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Terminal or metastatic disease\n* Pre-existing taste or smell disorders (e.g., anosmia, dysgeusia, neurological syndromes, etc.)\n* Known allergies to any substances used in taste and chemesthetic function tests (e.g., quinine dihydrochloride, monosodium L-glutamate, capsaicin, etc.)\n* Receiving neoadjuvant or adjuvant chemotherapy within research protocols\n* Lack of signed written informed consent","ALL","18 Years",{"count":59,"type":22},40,"The goal of this observational study is to examine how frequently changes in taste occur in people with early-stage breast cancer who receive chemotherapy. It will also look at how these taste changes affect nutrition and quality of life. The main questions this study aims to answer are:\n\n* How many participants develop changes in taste during chemotherapy?\n* How do these changes affect eating habits, nutrition, and daily life?\n\nParticipants are women with non-metastatic breast cancer who are receiving chemotherapy before or after surgery.\n\nResearchers will use standardized taste tests to measure how well participants can perceive different flavors. These tests are designed to provide accurate and reproducible results.\n\nParticipants will:\n\n* Take part in taste tests during their chemotherapy treatment\n* Have their nutritional status evaluated\n* Answer questions about their quality of life",[62,63,64,65,66,67,68,69],"Taste Disorders","Breast Cancer","Quality of Life","Taste Perception","Dysgeusia","Chemotherapy Effects","Nutritional Status","Sensory Testing",[66,71,29,72,73,74,75,76],"Taste disorders","Quality of life","Taste perception","Chemotherapy effects","Nutritional status","Sensory testing","NOT_YET_RECRUITING","2025-12-24",{"date":80,"type":39},"2026-01-05",{"date":82,"type":22},"2026-01",{"date":84,"type":22},"2027-12",{"name":45,"class":46},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":47},"100615956","a-model-for-continuous-care-of-fragile-patients-100615956","NCT07299344","A Model for Continuous Care of Fragile Patients","Un Modello di Presa in Carico Continua Del Paziente Fragile","AFTER","Inclusion criteria:\n\n* Adult medically fragile patients with one of the following neurological conditions: mild-to-moderate stroke (Rankin ≤ 3), Multiple Sclerosis (EDSS ≤ 6.5), Parkinson's disease or parkinsonisms, neuromuscular diseases; or orthopedic conditions: femur, pelvis, or humerus fracture.\n* Able to walk independently, with or without assistive devices.\n* Adequate cognitive function (MMSE ≥ 24).\n* Patient or caregiver owns and can use a mobile device with internet\u002Fdata connection.\n* Presence of a cognitively capable, cooperative caregiver willing to participate in the study.\n\nExclusion criteria:\n\n* Patients with severe neurological or orthopedic conditions who cannot walk independently, even with assistive devices.\n* Patients with moderate or severe cognitive impairment (MMSE \\\u003C 24).\n* Patients with Barthel Index \\> 60.\n* Patients or caregivers unable to use a mobile device or without internet\u002Fdata connection.\n* Patients without a cooperative, cognitively capable caregiver.",{"count":95,"type":22},100,"This observational study aims to monitor functional status and identify potential declines in the functioning of medically fragile patients with neurological and\u002For orthopedic conditions, representing an added value for ensuring appropriate patient management. This approach improves system efficiency and supports a proactive strategy that promotes the appropriate use of resources.",[98,99,100,101],"Neurological Disorders","Orthopedic Disorders","Functional Decline","Fragile and More Vulnerable",[103,100,104,98,105,106,107,108,109,110,111],"Functional Monitoring","Medically Fragile Patients","Orthopedic Conditions","Rehabilitation","Proactive Care Model","Continuous Patient Management","Rehabilitation Setting","Early Detection of Functional Changes","telemedicine","2025-12-09",{"date":114,"type":39},"2025-12-23",{"date":116,"type":22},"2025-12",{"date":118,"type":22},"2028-06",{"name":45,"class":46},""]